True, a green light here will be a good catalyst. But don't forget deal negotiations can and do take time...8 months, a year, sometimes more...lots to discuss, lots to flesh out...and perhaps even more in our case (think wide potential applications, multi actionary, DMOAD boost potentially (my views)...and global potential with decent numbers)....just one more attractive feature for a Big Partner is that we have a difficult molecule to copy, this could add some value to our underlying.
We have a clue that there have been discussions as Paul mentioned but this will increase potentially after many potential suitors see that the FDA have vetted us and we are allowed 'in'.
DYOR applies
research reports and media, page-2014
-
- There are more pages in this discussion • 2,179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |